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Abstract
A retrospective meta-analysis of magnetic resonance imaging voxel-based morphometry studies proposed that
reduced gray matter volumes in the dorsal anterior cingulate and the left and right anterior insular cortex—areas that
constitute hub nodes of the salience network—represent a common substrate for major psychiatric disorders. Here,
we investigated the hypothesis that the common substrate serves as an intermediate phenotype to detect genetic risk
variants relevant for psychiatric disease. To this end, after a data reduction step, we conducted genome-wide
association studies of a combined common substrate measure in four population-based cohorts (n= 2271), followed
by meta-analysis and replication in a fifth cohort (n= 865). After correction for covariates, the heritability of the
common substrate was estimated at 0.50 (standard error 0.18). The top single-nucleotide polymorphism (SNP)
rs17076061 was associated with the common substrate at genome-wide significance and replicated, explaining 1.2%
of the common substrate variance. This SNP mapped to a locus on chromosome 5q35.2 harboring genes involved in
neuronal development and regeneration. In follow-up analyses, rs17076061 was not robustly associated with
psychiatric disease, and no overlap was found between the broader genetic architecture of the common substrate
and genetic risk for major depressive disorder, bipolar disorder, or schizophrenia. In conclusion, our study identified
that common genetic variation indeed influences the common substrate, but that these variants do not directly
translate to increased disease risk. Future studies should investigate gene-by-environment interactions and employ
functional imaging to understand how salience network structure translates to psychiatric disorder risk.
Introduction
Numerous studies have identified regional differences in
the brain structure of psychiatric patients and described
both transdiagnostic and disorder-specific processes of
gray matter (GM) reduction in patients1–8. One of these
reports was the large retrospective meta-analysis of
193 studies by Goodkind et al. that compared 7381
psychiatric patients from six diagnostic groups (schizo-
phrenia, bipolar disorder (BD), major depressive disorder
(MDD), addiction, obsessive-compulsive disorder, and
anxiety) with 8511 psychiatrically healthy controls using
voxel-based morphometry (VBM) from structural mag-
netic resonance imaging (MRI)1. Across all diagnoses,
they found that GM volumes were lower in the left and
right anterior insular cortices (AIC) and the dorsal ante-
rior cingulate cortex (dACC). Subsequentially, they per-
formed structural and functional connectivity analyses
and confirmed that these three regions were tightly con-
nected and represent hub nodes of the salience net-
work:1,9,10 This network serves stimulus selection,
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controls the focus of attention, and is involved in the
selection of goal-directed behavior and in saliency
detection of exogenous or internal cues9–11. Independent
studies indicate that functional differences in salience
processing in these brain regions are associated with
several neuropsychiatric disorders and their progres-
sion11. Eventually, Goodkind et al. hypothesized that
lower GM of this network represents a common neuro-
biological substrate for psychiatric disorders1.
However, the etiology of the common substrate reduc-
tions has not been investigated so far and remains unclear.
One possible explanation involves the loss of GM at dis-
ease manifestation and during the further course of dis-
ease, implying a regionally specific vulnerability toward a
degenerative process—similar to known neurodegenera-
tive disease entities12,13. An alternative explanation
implies that reduced GM exists before disease onset,
shaped by genetic or early environmental influences such
as childhood adversity:14 Here, premorbid structural
abnormalities of the salience network could increase a
subject’s vulnerability to psychiatric disease. More
recently, structural salience network integrity was repor-
ted to mediate between polygenic risk for schizophrenia
and auditory hallucinations15. A third explanation
involves brain-aging processes that occur in a network-
dependent way and often with a strong non-linear com-
ponent:16–18 Here, accelerated aging could increase the
disease risk over the lifespan by genetic or environmental
factors. All three explanation models might apply in
parallel and lead to combined effects at the
morphological level.
Many studies have analyzed genetic risk factors for
psychiatric disorders such as schizophrenia, BD, and
MDD19. These disorders show substantial heritability20
and are genetically correlated with each other21,22.
Genome-wide association studies (GWAS) identified
single-nucleotide polymorphisms (SNPs) contributing
risk for several psychiatric disorders, suggesting pleio-
tropy and partially overlapping etiologies22,23. Imaging
genomics is a growing discipline that exploits imaging-
based measures to explore the genetic basis of brain
organization24. The clinical value of this concept to detect
risk variants for psychiatric disease, however, depends on
a detectable correlation between the intermediate phe-
notype and the clinical level. Following this line of
thought, the common substrate suggested by Goodkind
et al. is a promising intermediate phenotype, particularly
due to its transdiagnostic effects.
The present study aimed to identify genetic variants
influencing the substrate in the general population. As a
conceptual decision, patient cohorts were not included in
our genetic analyses to avoid any interference with sec-
ondary disease effects on the common substrate, such as
treatment effects or other disease-related epiphenomena.
Our imaging analyses involved a prospective, harmonized
VBM preprocessing protocol applied to high-resolution
structural MRI data of five population-based cohorts. To
account for the network character of the three common
substrate regions, we combined them into a single marker
using principal component analysis (PCA). We analyzed
the first principal component of the common substrate
(CCS) of the population-based cohorts through GWAS,
followed by meta-analysis. As our main result, we iden-
tified a novel genetic locus significantly associated with
the CCS. In a series of secondary analyses, we char-
acterized the genetic relationship between the CCS and
risk for psychiatric disorders and investigated a potentially
modulating role of age.
Methods and materials
Sample description
For the GWAS, 3136 individuals from five population-
based cohorts were pooled. Four cohorts were used in the
discovery (1000BRAINS25, n= 539; CONNECT10026,
n= 93; BiDirect27, n= 589; SHIP-228, n= 1050; total n=
2271) and the second-largest cohort available was used in
the replication stage (SHIP-Trend28, n= 865). For follow-
up analyses, three psychiatric patient/control cohorts with
1978 patients and 1375 controls were used, BiDirect (n=
582 MDD patients; n= 311 healthy controls29), Max
Planck Institute of Psychiatry (MPIP) (n= 385 MDD
patients; n= 197 healthy controls30,31), and FOR2107
(n= 769 MDD, n= 127 BD, n= 72 schizophrenia, and
n= 43 schizoaffective patients; n= 867 healthy con-
trols32,33). The BiDirect cohort is a prospective observa-
tional study27. Probands were recruited in the area of
Münster and underwent a structured clinical interview for
DSM-IV axis I disorders and all MDD patients received
treatment for acute depression27. The MPIP cohort
represents subsamples of the Munich Antidepressant
Response Signature study, an observational study on
psychiatric in-patients treated for MDD30, and the
recurrent unipolar depression study, a cross-sectional
case/control imaging genetics study31 (see5,6 for diag-
nostic instruments). FOR2107 is an ongoing multicenter
study recruiting from the areas of Marburg and Münster
in Germany32. All subjects underwent a structured clinical
interview for DSM-IV axis I disorders, administered by
trained clinical raters. Basic demographic characteristics
of the cohorts can be found in Supplementary Tables S1
and S2. The studies were approved by the local ethics
committees; all participants provided written informed
consent.
VBM preprocessing and extraction of regional and total
GM volumes
VBM-like preprocessing with MATLAB-based SPM
(version 8, https://www.fil.ion.ucl.ac.uk/spm/software/
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spm8/) and the VBM8 toolbox (version r445, http://dbm.
neuro.uni-jena.de/vbm8/) were used to process all T1-
weighted images (n= 3136 for the GWAS and n= 3361
for the patient/control analyses). Processing was per-
formed locally by the participating sites and comprised
the following steps: (i) spatial registration to a reference
brain in MNI152 space, (ii) segmentation of T1-weighted
images into GM, white matter, and cerebrospinal fluid by
a three-step algorithm implemented in the VBM8 tool-
box, (iii) bias correction of intensity non-uniformities, (iv)
application of the diffeomorphic normalization algorithm
DARTEL for iterative linear and non-linear spatial nor-
malization of the GM and white matter maps to MNI
space (IXI555 template)34, (v) non-linear-only Jacobian
modulation to correct for linear global scaling effects
while preserving local GM volumes. The quality of pro-
cessed GM segments in MNI space was assessed using the
“Check sample homogeneity using covariance” function in
VBM8. Three spatially disjunct regional GM volumes,
based on binarized versions of the joint result areas from
the study by Goodkind et al.1, and total GM volume were
extracted.
Extracted GM volumes were, separately for each cohort,
corrected for age, age2, and sex in multiple linear
regression models. To allow for a valid interpretation of
the individual coefficients, we conducted a
Gram–Schmidt orthonormalization of age (first term) and
age2 (second term) in R v.3.5.2, using the function QR of
the package matlib (see the Supplementary Material).
Handedness was used as an additional covariate for
1000BRAINS, CONNECT100, and BiDirect, coil type for
the MPIP sample, as well as body coil type and site for
FOR2107. Residuals of these regional volume regression
models were combined using PCA to create a single
measure, which we named the CCS (Fig. 1).
Genotyping, quality control, and imputation
DNA extraction and genome-wide genotyping were
conducted as described before28,31,35–37. Genotyping
was carried out on different Illumina and Affymetrix
microarrays (see the Supplementary Methods and Sup-
plementary Table S3). Quality control and imputation
were conducted separately for each genotyping batch,
using the same protocols, in PLINK, R, and XWAS38,39.
Genotype data were imputed to the 1000 Genomes
phase 1 reference panel using SHAPEIT and
IMPUTE240,41, as described in the Supplementary
Methods and previously42. The population substructure
of all five GWAS cohorts is shown in Supplementary
Fig. S1.
Heritability estimation and GWAS
The SNP-based heritability of the CCS was estimated
using genome-wide complex trait analysis on a combined
sample of the imputed data from all five cohorts43 (see the
Supplementary Methods). GWAS was conducted sepa-
rately per cohort using PLINK with ancestry components
as covariates. Variants on the X chromosome were ana-
lyzed separately by sex, followed by p value-based meta-
analysis to allow for different effect sizes per sex.
A two-stage design was implemented for the GWAS,
using four cohorts as the discovery sample and SHIP-
Trend as an independent replication sample. The cohorts
were combined with fixed-effects meta-analysis using
METAL44. There was no indication for genomic inflation
of the GWAS test statistics in the single cohorts or the
meta-analysis (λ1000= 1.01, see Supplementary Table S4
and Supplementary Fig. S2).
Linkage disequilibrium (LD) was analyzed using the
European 1000 Genomes CEU population in LDmatrix45.
The two SNPs that showed the most robust genome-wide
support (p < 5 × 10−8) for an association in the discovery
stage and were partially independent of each other (LD r2
< 0.5 with more strongly associated variants) were carried
forward to the replication stage. Here, a one-sided p value
<α= 0.05/2 (correcting for two LD-independent variants)
was considered as a successful replication. See the Sup-
plementary Methods for a detailed description of herit-
ability and GWAS methods.
Gene-set analyses
Gene-set analyses were conducted on the meta-analysis
of the discovery- and replication-stage GWAS, using 674
REACTOME gene sets containing 10–200 genes curated
from MsigDB 6.246. Only SNPs within gene boundaries
were mapped to RefSeq genes (0 bp window). Analyses
were conducted in MAGMA v1.07 using both mean and
top SNP gene models47 and in MAGENTA v2 using a top
SNP approach48. Here, false discovery rates were calcu-
lated to correct for multiple testing.
Comparison to published GWAS of psychiatric disorders
and polygenic score analyses
For genome-wide comparisons between our GWAS
meta-analysis and published GWAS of psychiatric dis-
orders, summary statistics from the following Psychiatric
Genomics Consortium (PGC) GWAS were used: cross-
disorder 201922, BD 201949, MDD 2018 (with
23andMe)50, and schizophrenia 201451. For additional
comparisons, the following GWAS were used: IFGC
behavioral frontotemporal dementia (bvFTD) 201452,
longevity 85/90 201453, and three different GWAS from
2017 on epigenetic accelerated aging (EAA):54 accelerated
aging in all examined brain regions, accelerated aging in
prefrontal cortex, and neuronal proportion in the pre-
frontal cortex.
To further characterize the relationship between the
CCS and risk for psychiatric disorders, we ran four
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analyses using GWAS summary statistics from published
PGC studies, following a published, well-acknowledged
workflow55. Polygenic scores (PGSs) were calculated and
analyzed in R using imputed genetic data56,57. Here, we
used the PGC GWAS as training and our population-
based GWAS cohorts as test data. Furthermore, we also
calculated PGS using the CCS GWAS summary statistics
as training and the patient/control cohorts as test data.
We ran LD score regression (LDSC) comparing the
genetic correlation of published GWAS to the CCS
GWAS summary statistics with standard settings58,59. We
analyzed whether the order of SNPs ranked by their
association strength was random between studies using
rank–rank hypergeometric overlap (RRHO) tests60. For
this analysis, variants were LD-pruned in the 1000 Gen-
omes phase 3 EUR subset61. Binomial sign tests were
conducted on LD-clumped variants in R (binom.test) to
analyze whether SNPs associated with the CCS at either
p < 0.05 or p < 1 × 10−5 showed the opposite direction of
effects in other GWAS more often than expected by
chance. For additional details on these analyses, see the
Supplementary Methods.
Fig. 1 Generation of the component of the common neurobiological substrate (CCS) and genome-wide association study (GWAS) analysis
workflow. A, B Comparison between the CCS and the three individual volumes (A) and the residuals of the three volumes after correction for
covariates (B). AIC anterior insula cortex, dACC dorsal anterior cingulate cortex. C Histograms of the three extracted volumes and the CCS. Note that
A–C show combined data from all five GWAS cohorts. Correlations were left and right AIC: r= 0.65, left AIC and dACC: r= 0.52, right AIC and dACC: r
= 0.46. D GWAS analysis workflow. All measures were extracted using NLO-based Jacobian modulation. All GM volumes were corrected for age, age2,
and sex as covariates; handedness was used as an additional covariate for the three samples 1000BRAINS, CONNECT100, and BiDirect. PCA: principal
component analysis, LD: linkage disequilibrium.
Andlauer et al. Translational Psychiatry          (2021) 11:192 Page 4 of 13
Secondary analyses of age-interaction effects
We explored the possibility that the original VBM stu-
dies entering the meta-analysis of Goodkind et al.1 picked
up age-by-diagnosis effects by analyzing patient/control
cohorts and by verifying that our main genetic association
was not age-dependent. We performed secondary ana-
lyses that probed (a) the possibility of “accelerated aging”
of the CCS phenotype in psychiatric disorders and (b) the
possibility of heterogeneity of the SNP effect across dif-
ferent age ranges.
Results
Combination of the three brain regions
To analyze a combined measure of the published
common neurobiological substrate for psychiatric dis-
orders1, we combined the volumes of the left AIC, right
AIC, and dACC by PCA. The first principal component,
which we refer to as the CCS, explained 66.5% of the
phenotypic variance of the three volumes and 55.4% after
correction of the volumes for covariates (Fig. 1 and Sup-
plementary Methods).
Heritability of the CCS
After correction for covariates, the CCS showed a SNP
heritability estimate of h2g= 0.50 (standard error (SE)=
0.18; p value= 0.0033).
GWAS of the CCS
In the discovery-stage GWAS (Supplementary Fig. S2A
and Supplementary Table S4), 12 SNPs on chromosome
5q35.2 showed genome-wide significant associations with
the CCS (significance threshold p < 5 × 10–8; Fig. 2A and
Supplementary Table S5). Most of these variants were
highly correlated with each other (Supplementary Table
S6). The two partially LD-independent SNPs (pairwise LD
r2= 0.267 in CEU samples) with the most robust support
for an association were analyzed further (Fig. 2B). Of
these, the minor allele T of the SNP rs17076061 (fre-
quency in our GWAS cohorts: 0.36, Fig. 2C) was sig-
nificantly associated in the replication cohort in the same
direction (discovery: β=−0.22 standard deviations (SD)
(SE= 0.04), p= 1.51 × 10–8; replication: β=−0.15 (SE=
0.07), one-sided p= 9.91 × 10–3, Supplementary Fig. S3)
and was also the top-associated variant in the genome-
wide meta-analysis of discovery and replication samples
(β=−0.21 (SE= 0.03), p= 1.46 × 10–9; Fig. 2D, Supple-
mentary Table S5, Supplementary Figs. S2B, S4, and S5).
SNP rs17076061-T was associated with the CCS at
genome-wide significance but not with the three single
region volumes or the whole-brain GM volume (Table 1).
After z-score transformation to allow effect size com-
parisons, the effect size was larger for the CCS (−0.159
SD) than for the total GM (−0.099 SD).
Gene-set analyses
In two separate gene-set analyses using GWAS meta-
analysis results, four pathways were significantly asso-
ciated with the CCS. The top-associated pathway in both
analyses (MAGMA: adjusted p= 2.2 × 10–3; MAGENTA:
false discovery rate q= 2.4 × 10–3) was “SEMA3A-Plexin
repulsion signaling by inhibiting Integrin adhesion”
(https://www.reactome.org/content/detail/R-HSA-
399955). Please see Supplementary Tables S7 and S8 for
the full results of these analyses.
Comparison of the top GWAS SNP and the genetic
architecture of the CCS with genetic risk for disease
To investigate whether rs17076061 is associated with
risk for common psychiatric disorders, we looked up the
SNP in published results from large GWAS of psychiatric
disorders by the PGC (cross-disorder22, BD49, MDD50,
and schizophrenia51). Here, the cross-disorder GWAS
showed the strongest effect, albeit not significant after
correction for multiple testing (OR= 1.035, unadjusted
one-sided p= 0.048; Supplementary Table S9). Next, we
conducted genome-wide comparisons: using LDSC, we
found no significant genetic correlation between the CCS
GWAS and the four psychiatric GWAS (Table 2 and
Supplementary Table S10). Furthermore, RRHO tests
showed no significant overlap of SNPs ranked by their
association strength (Table 2, Supplementary Table S11,
and Supplementary Fig. S6). In binomial sign tests, CCS-
associated variants did not show the opposite effect
direction in the psychiatric disorder GWAS more often
than expected by chance (Table 2 and Supplementary
Table S12).
Analysis of polygenic scores
Next, we calculated PGSs based on the four PGC
GWAS (psychiatric cross-disorder, MDD, BD, schizo-
phrenia) as training data and analyzed associations of
these disease-associated PGSs with the CCS in our
population cohorts. None of the PGSs were associated
with the CCS after correction for multiple testing (Table
2, Supplementary Table S13, and Supplementary Fig. S7).
Last, we inverted the direction of the approach and built
a PGS based on our CCS GWAS as training data, using
ten different p value thresholds, and compared it between
patients and controls from four clinical diagnoses (MDD,
BD, schizoaffective disorder, and schizophrenia) as avail-
able from three patient/control cohorts (BiDirect, MPIP,
FOR2107). We expected the CCS PGS to be lower in
psychiatric patients. No consistent results were observed
regarding the expected direction of the patient/control
comparisons and a specific threshold, and no single effect
proved robust to multiple testing correction (Supple-
mentary Table S14).
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Analyses of age-dependent effects
In an imaging meta-analysis of our three MDD/control
cohorts (BiDirect, MPIP, FOR2107), we confirmed that the
CCS was reduced in MDD patients compared to controls
(p= 1.3 × 10-7; Fig. 3A and Supplementary Table S15). In
the transdiagnostic FOR2107 cohort, the median CCS
showed a stepwise decrease along the affective-psychosis
axis (controls: median= 0.18; MDD: median=−0.010,
comparison to controls: p= 3.9 × 10−3; BD: median=
−0.35, p= 2.8 × 10−5; schizoaffective disorder: median=
−1.13, p= 2.6 × 10−8; schizophrenia: median=−0.58, p=
6.6 × 10−10; combined analysis of all four diagnostic groups
in FOR2107: p= 1.5 × 10−7; Fig. 3A, Supplementary Table
S15, and Supplementary Fig. S8). This finding strongly
affirmed the results of Goodkind et al.1.
In these analyses, we noticed a possible influence of age
on the association between the patient/control status and
the CCS. When adding a linear and quadratic age-
interaction term to the MDD regression models, the lin-
ear interaction term was not significant (p= 0.72). How-
ever, the age2-by-diagnosis interaction term was
significant (p= 0.014), pointing to a possible non-linear
age dependency in MDD. No such effect was detected in
the other diagnostic groups (Fig. 3B and Supplementary
Table S15). To explore non-linear age dependencies in a
complementary approach, we stratified all patient/control
cohorts into five non-overlapping age groups (Fig. 3C).
Heterogeneity in a meta-analysis of the CCS associations
stratified by age would have indicated strong non-linear
effects of age on the CCS. However, we detected no
Fig. 2 Presentation of the genome-wide association study (GWAS) results. A Manhattan plot showing the strength of evidence for an
association (p value) in the discovery stage component of the common neurobiological substrate (CCS) GWAS. Each variant is shown as a dot, with
alternating shades of blue according to chromosome; the top-associated locus 5q32.2 is labeled with a red diamond. The red line marks the genome-
wide significance level. B Matrix of the pairwise linkage disequilibrium (LD) pattern (1000 Genomes population CEU) between the 12 variants that
reached genome-wide significance in the discovery GWAS. The two variants rs17076061 and rs72088023 (r2= 0.267) showed the strongest support
for an association in their respective LD blocks and were analyzed in the replication stage. All other variants had pairwise LD > 0.5 with either of these
two variants, their association strengths are provided for comparison only. PDisc. discovery stage GWAS p value, pRepl.(1s) one-sided p value in the
replication cohort, Mbp mega base pair. C Regional association plot of the top-associated locus after pooled analysis of the discovery stage GWAS
and the replication sample. The dot color indicates LD with the lead variant (rs17076061; pink). Gray dots represent signals with missing LD r2 values.
cM: centimorgan. D Forest plot of the pooled analysis of the replicated variant rs17076061 in discovery and replication cohorts. D. P.: pooled analysis
of discovery stage cohorts, Repl.: replication, Pool.: pooled analysis of the discovery GWAS and the replication cohort SHIP-Trend.
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significant heterogeneity between the age groups (Q=
3.21, p= 0.52; Fig. 3C and Supplementary Table S16).
When adding interaction terms to the model, neither
the age-by-SNP (p= 0.48) nor the age2-by-SNP (p= 0.50)
interaction became significant in the meta-analysis of the
five GWAS population cohorts, while the main SNP effect
remained stable (Supplementary Table S17). Similarly,
when stratifying the analysis by age groups, the SNP main
effect size varied, yet without significant heterogeneity
(Q= 2.25, p= 0.69; Fig. 3D and Supplementary
Table S17).
To investigate whether our specific implementation of
the global brain size correction influenced the association
results, we switched from non-linear only Jacobian mod-
ulation of the GM probability maps to full Jacobian
modulation, with the total intracranial volume entered as
an explicit volumetric covariate. Our association results
remained stable, independent of the correction method
used (Supplementary Methods and Supplementary
Table S15).
Comparison of the genetic architecture of the CCS with the
genetics of aging traits
To further explore whether genetic variants associated
with the CCS might influence aging-related processes, we
compared our CCS GWAS results with GWAS for EAA54
and longevity53. The common substrate regions represent
the salience network, which is specifically prone to neu-
rodegeneration in bvFTD12,62, a subtype of fronto-
temporal dementia with severe executive disturbances
and personality changes. Therefore, we also analyzed a
possible overlap with GWAS results for bvFTD52. SNP
rs17076061 showed no significant association in any of
these GWAS (Supplementary Table S9). Single findings
for longevity and EAA were nominally significant in PGS
analyses and sign tests. However, overall, no significant
genetic overlap with any of these GWAS was found with
LDSC (Supplementary Table S10), RRHO tests
Table 1 Association results from the genome-wide meta-
analysis of discovery and replication samples in different
gray matter (GM) regions.
rs17076061 Effect size SE p value
CCS −0.159 0.026 1.41 × 10−9
Left AIC −0.142 0.026 7.00 × 10−8
Right AIC −0.124 0.026 2.63 × 10−6
dACC −0.083 0.026 1.77 × 10−3
Total gray matter −0.099 0.026 1.85 × 10−4
For this comparison, all measures were centered and scaled using z-score
transformation before the analysis to make the effect sizes of the different
measures comparable. The unit of the effect sizes is thus standard deviation
(SD). Accordingly, the CCS coefficients shown here differ from the ones
presented in Fig. 2 and Supplementary Table S5. The effect size refers to the
minor allele T. All measures were extracted using non-linear only (NLO)-based
Jacobian modulation.
AIC anterior insula cortex, dACC dorsal anterior cingulate cortex, SE
standard error.
Table 2 Comparisons of the component of the common
neurobiological substrate (CCS) and the CCS genetic
architecture with psychiatric disorders.
LD score regression (LDSC)
GWAS comparison rg p value
Psychiatric cross-disorder 0.0005 0.99
Bipolar disorder 0.17 0.08
Major depression −0.03 0.75
Schizophrenia 0.08 0.38
Rank–rank hypergeometric overlap (RRHO)
GWAS comparison Overlap p value
Psychiatric cross-disorder 0.29 0.53
Bipolar disorder 0.21 0.06
Major depression 0.04 0.18
Schizophrenia 0.02 0.15
Binomial sign tests (p < 0.05)
GWAS comparison Probability p value
Psychiatric cross-disorder 0.50 0.77
Bipolar disorder 0.50 0.67
Major depression 0.50 0.82
Schizophrenia 0.50 0.64
Binomial sign tests (p < 1 × 10−5)
GWAS comparison Probability p value
Psychiatric cross-disorder 0.33 0.93
Bipolar disorder 0.54 0.50
Major depression 0.33 0.93
Schizophrenia 0.54 0.50
Polygenic scores (PGS)
Training GWAS Effect size p value pT
Psychiatric cross-disorder −0.78 0.30 5 × 10−8
Bipolar disorder −0.64 0.05 1 × 10−7
Major depression −5.01 0.31 1 × 10−2
Schizophrenia −0.58 0.24 1 × 10−7
Details on the four training genome-wide association studies (GWAS) datasets
are provided in the Methods section. LDSC: linkage disequilibrium score
regression using genome-wide summary statistics (Supplementary Table S10); rg
genetic correlation. RRHO: rank–rank hypergeometric overlap test showing the
relative overlap of genome-wide summary statistics (Supplementary Table S11).
Sign tests one-sided binomial sign tests for CCS GWAS p value thresholds p <
0.05 and p < 1 × 10−5 and the corresponding probability of success (Supple-
mentary Table S12). PGS association of polygenic scores with the CCS; pT
training GWAS data p value threshold; effect size linear regression effect size at
the pT showing the strongest support for an association (see Supplementary
Table S13 for results of all ten thresholds); p value: one-sided p value not
corrected for multiple testing. The significance level adjusted for multiple testing
was α= 0.05/(10 × 4)= 0.00125.
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(Supplementary Fig. S9 and Supplementary Table S11),
sign tests (Supplementary Table S12), or PGS analyses
(Supplementary Fig. S7 and Supplementary Table S13)
after correction for multiple testing.
Discussion
In the present study, we investigated the genetic archi-
tecture of an MRI-based volumetric marker that has
previously been identified as a common neurobiological
substrate for major psychiatric disorders1, mapping to
areas of the salience network. As the primary analysis, we
conducted a population-based GWAS on this substrate
that was calculated from the original three-region sub-
strate using dimensional reduction by PCA. Thereby, we
generated the CCS, a construct that simplified our genetic
analyses while retaining a large fraction of the phenotypic
variance. In secondary analyses, we studied the relation-
ship between the CCS and risk for psychiatric disease as
well as age-by-SNP and age-by-diagnosis effects on the
CCS. Overall, our study produced three main findings.
First, the minor allele T of the intergenic SNP
rs17076061 was associated with a decreased CCS at
genome-wide significance and replicated. The association
signal from the CCS was stronger than those from the
three separate regions indicating that our approach sta-
bilized the CCS association by reducing the statistical
noise. The SNP maps directly to an evolutionarily con-
strained element in mammals63, supporting a regulatory
Fig. 3 Analyses of age-by-diagnosis and age-by-SNP effects on the component of the common neurobiological substrate (CCS). A A
significant smaller CCS was observed in MDD (BiDirect, MPIP, FOR2107), BD (FOR2107), SZA (FOR2107), and SCZ (FOR2107) patients, affirming the
transdiagnostic finding by Goodkind et al.1 (Supplementary Table S15). B Age2 trajectories of the patient/control groups plotted for each cohort. A
non-linear, quadratic age dependency was observed in MDD (pooled MPIP, BiDirect, FOR2107), but no other diagnostic group. Data points represent
the CCS after residualization against all covariates except for age and age2 (separate fit for patients and controls (Supplementary Table S15). C Age-
stratified analyses of the association between diagnosis and the CCS using five age groups in the combined patient/control cohorts (with cohort as a
covariate). No significant heterogeneity was observed. Size and color of the effect sizes per bin are proportional to the sample size. D Age-stratified
analyses of the association between the top SNP (rs17076061) and the CCS using five age groups in the combined five population-based GWAS
cohorts (with cohort modeled as a covariate). No significant heterogeneity between the age groups was observed. Size and color of the effect sizes
per bin are proportional to the sample size.
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role of the variant. The locus on chromosome 5q35.2
harbors several predicted, uncharacterized long intergenic
non-coding RNAs and two protein-coding genes expres-
sed in the brain with either psychiatric or neuroprotective
functions64–67. The latter genes are biorientation of
chromosomes in cell division 1 (BOD1) and stanniocalcin
2 (STC2), located 75 kbp downstream and 202 kbp
upstream of rs17076061, respectively.
The SNP is part of a significant expression quantitative
trait locus (eQTL) for STC2 in pancreatic tissue (p=
3.6 × 10−8). However, this eQTL was not significant in the
anterior cingulate cortex (p= 0.06), and the anterior
insula was not available in GTEx v868. Notably, the sample
size for the ACC was half of that for the pancreas,
decreasing the statistical power. In neurons, rs17076061
thus likely influences the expression of STC2, which
expresses a secreted glycoprotein with a possible auto- or
paracrine function. In the regulation of apoptosis, the
unfolded protein response promotes the expression of the
potentially neuroprotective STC2 in neuronal cells66,67.
Our second main finding is that the neurodevelop-
mental pathway “SEMA3A-Plexin repulsion signaling by
inhibiting Integrin adhesion” was significantly associated
with the CCS. Semaphorin-3A (SEMA3A) is a chemor-
epellent mediating axon guidance and a chemoattractant
for dendrite growth, whereas plexins are the signal-
transducing subunits of the Semaphorin-3A receptor.
Semaphorin-3A and Plexin-A2 are associated with dif-
ferent psychiatric disorders:69–72 Plexin-A2 is associated
with schizophrenia, anxiety, and MDD72,73, while
Semaphorin-3A is upregulated in the brain of schizo-
phrenia patients and has been suggested to contribute to
the synaptic pathology of the disorder70. Furthermore,
Semaphorin-3A may contribute to neurodegeneration in
Alzheimer’s disease71, and the pathway is important for
neuronal regeneration after brain trauma74.
A third set of analyses focused on the question whether
our approach—correlating a disease-associated structural
brain phenotype with population-based genomic variation
—would lead to the detection of genetic variants relevant
for psychiatric disorders. Here, we found a discrepancy
between detecting a genome-wide significant SNP
(rs17076061) on the one hand, while not detecting an
association between this SNP and major psychiatric
diagnoses (MDD, BD, and schizophrenia) on the other
hand. This finding obviously contradicts the latent
expectation that the CCS could represent a “risk endo-
phenotype” that exhibits a substantial heritability of 50%
in the studied population. Although our top SNP
explained only a small fraction of the CCS variance (R2=
1.2%, sample size-weighted mean across three cohorts),
there still remains a disconnection between this finding
and the lack of an observed psychiatric risk conveyed by
the SNP.
One explanation for this observation is the low corre-
lation between the CCS and psychiatric diagnoses:
Goodkind et al.1 used the revised activation likelihood
estimation (ALE) meta-analysis framework to test for a
spatial convergence of morphometric patient/control
differences and found the three-region substrate. How-
ever, ALE does not process effect sizes from the original
studies, which impeded a comparison with our results.
We thus analyzed patient/control cohorts of the affective-
psychosis spectrum to assess the CCS variance explained
by the diagnostic status, ranging from 1.0% for MDD to
4.2% for schizophrenia (R2). Therefore, in a model that
attributes disease risk to the presence of a smaller CCS
(less GM), we expect the risk effect mediated by a single
SNP to be very low. Compatible with this model, the
association of rs1707601 with disease risk was only
nominally significant in the large and most recent cross-
disorder study by the PGC (26,432 patients and 49,926
controls22). Evidence from large consortium studies
showed that psychiatric disease-specific PGSs explain only
a small fraction of the disease phenotype19. This, along
with the low disease/CCS correlation, may explain our
observation that PGSs calculated from published GWAS
were not associated with the CCS in our population-based
cohorts.
The polygenic nature of both the CCS and risk for
psychiatric disease demanded more detailed comparisons
between association signals from the CCS GWAS and
GWAS of major psychiatric disorders applying com-
plementary statistical approaches (LDSC, RRHO, binom-
inal sign tests). Our results suggest that no such genetic
overlap exists, adding our study to a line of similar pre-
vious reports: Large studies on MDD and schizophrenia,
for example, found only weak or no relationship between
the genetic architecture of these diagnoses and regional
brain volumes2,55,75–77. Similarly, a meta-analysis of
genetic factors influencing subcortical volumes in about
40,000 individuals identified no robust correlations
between subcortical volumes and BD or schizophrenia75.
One may speculate that differences between disease-
predisposing (“causal”) and secondary (“epiphenomeno-
logical”) brain changes (due to substance use or other
comorbidities) could play a role for this heterogeneity.
Methodologically, the analyses of genetic overlap, as
conducted by us and others61,75, investigated genome-
wide similarities between GWAS. If only some variants
showed a joint association or different loci exhibited
mixed effect directions, these methods could fail to detect
similarities. Similarly, our PGSs for a larger CCS were not
lower in psychiatric patients diagnosed with MDD, BD,
schizoaffective disorder, or schizophrenia. This finding
supports the hypothesis that the standard approach of
PGS, which only accounts for common additive effects,
does not adequately capture epistatic gene-by-gene or
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gene-by-environment effects that influence complex traits
and, even more, disease risk. Future studies are warranted
to explore such relationships based on models that allow
for non-additive, particularly interactive effects78.
Another possible explanation for the dissociation
between our genetic findings and disease risk is that other
premorbid environmental influences, such as the prenatal
environment or early life adversity, were not addressed in
our study. Such influences could aggravate a morpholo-
gical risk pattern without being directly reflected in
genetic associations. Well-documented examples for
these influences are specific correlations between early
childhood adversity and salience network dysfunction or
GM loss79–81. In this line of thinking, undetected envir-
onmental factors may have shaped the CCS beyond
genetic effects in our population cohorts. It is evident that
only longitudinal studies of patients and controls can
disentangle this challenging question, particularly as
longitudinal brain changes themselves show a significant
heritable component82.
In our attempt to understand the function of the top
SNP from our GWAS (rs17076061), we considered that
aspects of pathological aging (accelerated aging) could
play a role. In this regard, reports on different structural
brain markers suggest that several major psychiatric dis-
eases are associated with accelerated aging, with different
effect sizes and different regional patterns6,83. The sal-
ience network, in particular, is involved in an accelerated
cognitive decline during aging84. Beyond a cross-sectional
replication of small but robust CCS differences between
patients and controls, we recognized that the CCS could
harbor non-linear age-by-diagnosis interactions in MDD.
In fact, the SNP effect proved robust against the inclusion
of age-interaction terms, without significant heterogeneity
when analyzed in age-binned subgroups. These results
suggest that rs17076061 may have a stable effect on the
CCS over the adult lifespan. However, we could not
entirely exclude the influence of higher-order non-linear
deviations that we could not analyze in the present study.
Concordant with this observation, we did not find genetic
overlaps between our GWAS and GWAS of longevity
(representing an extreme form of healthy aging), or
bvFTD (representing an extreme form of salience network
degeneration). To clarify the relationship between the
CCS and a possibly accelerated salience network aging in
psychiatric disease, larger patient/control cohorts are
required that allow triple-interaction analyses (genetics,
disease status, and CCS).
Our study has several limitations. First, more compre-
hensive investigations of age dependencies would have
been possible from more homogeneous age distributions
in the population cohorts. Still, our main goal demanded
to assemble large samples, given the expected small
effects of common variants. Second, environmental fac-
tors such as childhood adversity were either not available
or acquired with heterogeneous instruments in the
population cohorts, preventing an inclusion of this
dimension as an important source of variance or inter-
action factor. Third, the operationalization of the CCS
followed the specific result map of Goodkind et al.1, which
is a sparse representation of the salience network. Data-
driven definitions, e.g., through structural covariance, as
exemplified before85, may capture a larger portion of the
volumetric variance of the salience network17,18.
In conclusion, we detected a replicable, genome-wide
significant association of a common variant (rs17076061)
with GM areas that represent hubs of the salience network
in adult individuals from the general population. The
genetic architecture of this network was not correlated with
genetic risk for major psychiatric disorders. Future gene-by-
environment interaction and functional imaging analyses
may enable us to understand how salience network struc-
ture translates to psychiatric disease risk.
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